Amgen Inc.’s stock AMGN tumbled 7.8% in early trade Tuesday, after the company said a mid-stage trial of its weight-loss ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% of their body weight in a mid-stage ...

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Shares of Amgen (AMGN) are down $11.49, or 4%, to $282.51 in pre-market trading after the company reported data at 52 weeks in a Phase 2 study ...

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while promising — ...

Amgen Inc (NASDAQ: AMGN) says patients on its weight-loss injection in a mid-stage trial weighed up to 20% less on average ...